Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vision Institute

Neither a doctor nor a teaching hospital

Research payments

$375,881

21 payments

Through program year 2025, Vision Institute is reported as receiving $375,881 in research payments, across 21 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $12,780 3
2023 Research $11,543 2
2022 Research $238,662 7
2021 Research $111,251 7
2020 Research $1,420 1
2019 Research $225 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $216,318 6 payments
  2. Novartis Pharmaceuticals Corporation $71,300 2 payments
  3. Alcon Research LLC $46,667 6 payments
  4. Aerie Pharmaceuticals, Inc. $41,300 5 payments
  5. Allergan Inc. $296 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-Center, Double-Masked, Randomized, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation with Lumify 0.025% in Adult Subjects with Ocular Redness $209,468 3 payments
  2. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $71,300 2 payments
  3. A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $41,300 5 payments
  4. A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $29,480 1 payment
  5. COMET Confirmatory Study $12,780 3 payments
  6. A Multi-Center, Double-Masked, Randomized, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation with Lumify 0.025% in Adult Subjects with Ocular Redness $6,850 3 payments
  7. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $4,000 1 payment
  8. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $407 1 payment
  9. Phase 2 Study of A New Ophthalmic Formulation of Cyclosporine Restasis X in Patients With Dry Eye Disease $225 1 payment
  10. A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease $71 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record